Does short-term androgen depletion add to high-dose radiotherapy (80 Gy) in localized intermediate-risk prostate cancer? Intermediary analysis of GETUG 14 randomized trial (EU-20503/NCT00104741).
B. M. Dubray
Research Funding - Ipsen
V. Beckendorf
No relevant relationships to disclose
S. Guerif
No relevant relationships to disclose
E. Le Prise
No relevant relationships to disclose
A. Reynaud-Bougnoux
No relevant relationships to disclose
J. M. Hannoun Levi
No relevant relationships to disclose
T. D. Nguyen
No relevant relationships to disclose
C. Hennequin
No relevant relationships to disclose
J. Cretin
No relevant relationships to disclose
M. Fayolle-Campana
No relevant relationships to disclose
J. Lagrange
No relevant relationships to disclose
J. Bachaud
No relevant relationships to disclose
D. Azria
Honoraria - Novartis; Roche
Research Funding - Novartis
A. Grangirard
No relevant relationships to disclose
P. Pommier
No relevant relationships to disclose
J. Simon
No relevant relationships to disclose
V. Harter
No relevant relationships to disclose
M. Habibian
No relevant relationships to disclose